Clinical Trials Sponsored by Novartis Pharmaceuticals

Total 21492 results

Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
Novartis
Novartis Vaccines; Chiron s.r.l. Beijing Representative Office

Completed

Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)

Influenza

China
Columbia University
Novartis

Recruiting

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

COVID-19 | Multiple Sclerosis

United States
Columbia University
Novartis

Recruiting

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)

Carcinoma, Renal Cell

United States
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Institut Bergonié
Novartis

Terminated

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response (AFR22)

Myeloid Leukemia, Chronic

France
GlaxoSmithKline
Novartis Vaccines

Completed

Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Virus Diseases | Tick Borne Encephalitis

Czechia
Mereo BioPharma
Novartis

Completed

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

Endometriosis

United States
GlaxoSmithKline
Novartis Vaccines

Completed

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Meningococcal Disease | Infections, Meningococcal

Taiwan
Stanford University
Novartis

Completed

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell, Peripheral | Bone Marrow Transplant Failure

United States, Canada
Northwestern University
Novartis

Completed

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Sarcoma | Brain and Central Nervous System Tumors

United States
Northwell Health
Novartis

Completed

Iron Overload in Pediatric Oncology Patients

Iron Overload

United States
Indiana University
Novartis

Completed

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis | NF1 | Neurofibromas

United States
Novartis
Genentech, Inc.

Completed

Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma

Asthma
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

Influenza, Human

Germany
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Augusta University
Novartis

Completed

GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients

Corneal Epithelium Defect

United States
Emory University
Novartis

Completed

A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

Head and Neck Neoplasms | Cancer of the Head and Neck

United States
Georgetown University
Novartis

Withdrawn

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Kidney Transplantation | Reperfusion Injury | Renal Transplantation
Aleris Helse
Novartis

Completed

A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO

Central Retinal Vein Occlusion | Macular Edema

Norway
Novartis
Genentech, Inc.

Completed

Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients

Asthma
Novartis
Schering-Plough

Completed

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Asthma

United States, Colombia, Peru
GOG Foundation
Novartis

Recruiting

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Endometroid Endometrial Cancer

United States
Region Skane
Novartis

Active, not recruiting

Treatment of NF1-related Plexiform Neurofibroma With Trametinib (plexifpc)

Child | Neurofibromatosis 1 | Neurofibroma, Plexiform

Sweden
Mereo BioPharma
Novartis

Completed

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

Chronic Obstructive Pulmonary Disease

Russian Federation, Bulgaria, Romania
PETHEMA Foundation
Novartis

Completed

A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers

Acute Myeloid Leukemia

Spain
Emory University
Novartis

Terminated

Phase II Study of Everolimus Beyond Progression

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
Vista Klinik
Novartis

Terminated

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept (ROBIN)

Neovascular Age-related Macular Degeneration

Switzerland
Emory University
Novartis

Completed

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

Thyroid Cancer

United States
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
GlaxoSmithKline
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

Streptococcus Agalactiae | GBS Disease

United States
Mereo BioPharma
Novartis

Terminated

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Pelvic Pain Associated With Refractory Endometriosis

United States, Puerto Rico
Mereo BioPharma
Novartis

Terminated

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

Acute Kidney Injury

Taiwan, United States, Israel
GlaxoSmithKline
Novartis Vaccines

Completed

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

Streptococcal Infections | Infections, Streptococcal

United States, Belgium, Czechia
Georgetown University
Novartis

Terminated

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Head and Neck Cancer | Colorectal Cancer

United States
McGill University
Novartis

Completed

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (IGLOO)

Multiple Sclerosis-Relapsing-Remitting

Canada
McMaster University
Novartis

Completed

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

Eosinophilic Bronchitis | Steroid and/or Prednisone Dependent Asthma

Canada
UConn Health
Novartis

Terminated

Vitamin D Deficiency in Patients With Hypertension

Hypertension | Vitamin D Deficiency

United States
Camurus AB
Novartis

Completed

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Neuroendocrine Tumors | Acromegaly

Germany, Sweden, France, Italy
Heidelberg University
Novartis

Completed

Study to Evaluate Imatinib in Desmoid Tumors

Desmoid Tumor | Aggressive Fibromatosis

Germany
Emory University
Novartis

Terminated

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Mucositis | Stage III Renal Cell Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIC Breast... and other conditions

United States
KU Leuven
Novartis

Unknown

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer (IPSOC-mamma)

ER Positive, HER2 Negative Breast Cancer Neoplasms

Belgium
Novartis
Mayo Clinic

Withdrawn

The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

Constipation and Dyspepsia
Bayside Health
Novartis

Completed

Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention

Osteopenia | Complications of Heart-lung Transplant | Other Complications of Lung Transplant
Duke University
Novartis

Withdrawn

A Panobinostat Presurgery (CLBH589C)

Recurrent Glioblastoma

United States
Novartis
Schering-Plough

Completed

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

France, Germany, Belgium, Italy, Turkey, Hungary, Argentina, Peru, United Kingdom, South Africa, Latvia, Lithuania, Romania, Chile, Ireland, Norway, Poland
Columbia University
Novartis

Unknown

Effects of Sandostatin LAR® in Acromegaly

Acromegaly

United States

3

Subscribe